Thymosin Beta-4 for Corneal Healing: The Eye Research
TB-500
60%
In the SEER-1 trial, 60% of neurotrophic keratopathy patients treated with 0.1% RGN-259 (thymosin beta-4 eye drops) achieved complete corneal healing versus 12.5% on placebo.
Sosne et al., Transl Vis Sci Technol, 2023
Sosne et al., Transl Vis Sci Technol, 2023
View as imageThe cornea is one of the few tissues in the body that must be perfectly transparent to function. Any scarring, persistent inflammation, or delayed healing after injury directly impairs vision. Thymosin beta-4 (Tb4), a 43-amino-acid peptide that sequesters monomeric actin and promotes cell migration, has emerged as one of the most studied peptide candidates for corneal wound healing. Its ophthalmic formulation, RGN-259, has completed multiple clinical trials for neurotrophic keratopathy and dry eye disease.[1]
For the broader biology of Tb4, see our pillar article on TB-500 (thymosin beta-4) and how thymosin beta-4 promotes cell migration and wound healing.
The corneal research is significant for two reasons. First, the eye is an immune-privileged site where peptide therapeutics can be applied topically, avoiding the systemic delivery challenges that limit most peptide drugs. Second, RGN-259 represents the furthest-advanced clinical program for Tb4 in any indication, making corneal healing the best evidence base for evaluating whether this peptide's preclinical promise translates to human patients.
Key Takeaways
- Thymosin beta-4 promotes corneal epithelial wound closure through actin-mediated cell migration; a synthetic peptide containing just the actin-binding domain reproduced this effect in rat corneal wounds[2]
- RGN-259 (0.1% Tb4 ophthalmic solution) achieved 60% complete corneal healing in neurotrophic keratopathy patients versus 12.5% placebo in the SEER-1 trial, but the SEER-3 Phase 3 trial did not meet its primary endpoint
- Tb4 has antimicrobial properties that reduce bacterial load in Pseudomonas aeruginosa keratitis when used alongside ciprofloxacin[3]
- Purinergic signaling (ATP/P2Y receptors) mediates Tb4's effects on corneal epithelial cell migration, providing a specific molecular mechanism[4]
- Recombinant human Tb4 modulates anti-inflammatory responses in corneal tissue, reducing NF-kB activation and pro-inflammatory cytokine expression[5]
- Tb4 protects corneal stromal keratocytes from ethanol-induced injury, relevant to post-surgical corneal damage from alcohol-based procedures[6]
How Tb4 Promotes Corneal Wound Healing
The corneal epithelium is a rapidly renewing tissue that normally heals small abrasions within 24 to 72 hours. But in conditions where the corneal nerves are damaged (neurotrophic keratopathy), where tear production is insufficient (severe dry eye), or where infection has destroyed tissue (bacterial keratitis), normal healing mechanisms fail. Tb4 addresses multiple aspects of this failure simultaneously.
Cell Migration Through Actin Sequestration
Tb4's primary biochemical function is sequestering G-actin (monomeric actin), which regulates the polymerization dynamics of the actin cytoskeleton. By modulating the actin pool, Tb4 promotes the formation of lamellipodia and filopodia, the cellular extensions that drive cell migration across wound surfaces.
Philp et al. (2003) demonstrated this directly in a corneal wound model. Both full-length Tb4 and a shorter synthetic peptide containing only the actin-binding domain (amino acids 17-23, the sequence LKKTET) promoted corneal wound healing in rats when applied topically. The actin-binding domain alone was sufficient to accelerate epithelial closure, confirming that Tb4's wound-healing effect is mediated through its interaction with actin dynamics.[2]
This built on the foundational work of Malinda et al. (1999), who first showed that Tb4 accelerates wound healing in skin through enhanced cell migration, angiogenesis, and collagen deposition.[7] The corneal application was a logical extension: if Tb4 promotes epithelial cell migration in skin, it should do the same in corneal epithelium, where migration across the wound bed is the rate-limiting step in healing.
Purinergic Signaling
Yang et al. (2020) identified a specific signaling pathway through which Tb4 promotes corneal epithelial cell migration. Tb4 activates purinergic signaling through P2Y receptors, which are ATP-responsive receptors on corneal epithelial cells. ATP release and P2Y receptor activation trigger intracellular calcium signaling that coordinates cytoskeletal reorganization and directional cell movement. Blocking P2Y receptors abolished Tb4's pro-migratory effect, establishing purinergic signaling as a necessary mediator.[4]
Anti-Inflammatory Action
Corneal injuries trigger inflammatory cascades that, if excessive, impair healing and cause scarring. Zhai et al. (2022) showed that recombinant human Tb4 (rhTb4) modulates anti-inflammatory responses in corneal tissue, reducing NF-kB pathway activation and suppressing production of TNF-alpha, IL-1beta, and IL-6. This anti-inflammatory effect is independent of the cell migration effect and operates through a different signaling pathway.[5]
Liu et al. (2022) demonstrated that Tb4 protects corneal stromal keratocytes from ethanol-induced injury, an effect relevant to laser-assisted eye surgery (LASEK and PRK), where dilute ethanol is applied to the corneal surface during the procedure. Tb4 reduced oxidative stress and apoptosis in keratocytes exposed to ethanol, suggesting a potential protective role in post-surgical recovery.[6]
Tb4 in Corneal Infections
Beyond wound healing, Tb4 has shown antimicrobial and immune-modulating effects in corneal infections.
Carion et al. (2020) tested Tb4 as an adjunct to ciprofloxacin in a mouse model of Pseudomonas aeruginosa keratitis, one of the most destructive corneal infections. The Tb4/ciprofloxacin combination reduced bacterial load, corneal opacity, and inflammatory infiltrate more effectively than ciprofloxacin alone.[3]
Wang et al. (2021) investigated the mechanism behind this adjunctive effect, showing that Tb4 influences polymorphonuclear neutrophil (PMN) function during P. aeruginosa keratitis. Tb4 modulated the neutrophil inflammatory response, reducing tissue-destructive inflammation while maintaining bacterial clearance.[8]
Sosne et al. (2023) proposed Tb4 as a novel adjunct for bacterial keratitis treatment more broadly, noting that current antibiotic therapy controls infection but does not address the inflammatory tissue destruction that causes permanent scarring and vision loss. Tb4's combination of antimicrobial, anti-inflammatory, and pro-healing effects could address all three components simultaneously.[1]
RGN-259: Clinical Trial Results
RGN-259 is a 0.1% thymosin beta-4 ophthalmic solution developed by RegeneRx (now through HLB Therapeutics subsidiary ReGenTree) for neurotrophic keratopathy and dry eye disease.
Neurotrophic Keratopathy
In the SEER-1 Phase 3 trial, 6 of 10 patients (60%) treated with RGN-259 achieved complete corneal epithelial healing compared to 1 of 8 (12.5%) on placebo. The trial was small but the effect size was large. Patients with neurotrophic keratopathy have impaired corneal nerve function, leading to persistent epithelial defects that standard lubricants cannot resolve.
However, the European SEER-3 Phase 3 trial did not meet its primary endpoint of statistically significant improvement in complete corneal healing at 4 weeks compared to placebo. The failure of the larger confirmatory trial illustrates a common challenge in peptide therapeutics: dramatic results in small trials do not always replicate in larger, more rigorous studies. The reasons for discordance between SEER-1 and SEER-3 are under analysis and may relate to differences in patient populations, severity criteria, or placebo response rates.
Dry Eye Disease
Earlier Phase 2 trials tested RGN-259 in the controlled adverse environment (CAE) model for dry eye. The peptide improved corneal staining scores (a measure of epithelial damage) and showed trends toward improvement in multiple symptom measures, though results were not uniformly statistically significant.
Comparison with Other Corneal Healing Peptides
Tb4 is not the only peptide studied for corneal healing. BPC-157, a 15-amino-acid peptide derived from human gastric juice, also promotes corneal epithelial defect healing in animal models. Lazic et al. (2005) showed BPC-157 accelerated corneal epithelial healing in rats, though through different mechanisms than Tb4 (BPC-157 acts primarily through VEGF and NO pathways rather than actin dynamics). For a direct comparison of these peptides' healing mechanisms, see TB-500 vs BPC-157.
Ying et al. (2023) provided a comprehensive review of Tb4's actin-binding modes and the clinical applications that follow from them, noting that the eye represents the most clinically advanced application but that Tb4's mechanism of action is not tissue-specific. The same actin sequestration and cell migration promotion that heals corneal wounds should work in any tissue where epithelial migration is the healing bottleneck.[9]
The challenge remains delivery. Tb4 has a short half-life and is rapidly degraded by peptidases. Topical eye drops provide high local concentrations with minimal systemic exposure, which is why the cornea has been the most successful therapeutic target. Engineered tandem Tb4 peptides with improved stability and scalability are in development to address these limitations. For Tb4's applications in other tissues, see TB-500 for muscle repair.
The Multi-Mechanism Advantage
What distinguishes Tb4 from other corneal healing approaches is its simultaneous action on multiple pathways. Current corneal wound treatments address individual components of the healing process: lubricants reduce friction, antibiotics fight infection, anti-inflammatories suppress immune damage, and bandage contact lenses protect the wound surface. Each addresses one piece of the puzzle.
Tb4 acts on at least four components simultaneously. It accelerates epithelial cell migration across the wound bed (the rate-limiting healing step). It reduces the inflammatory cascade that causes secondary tissue damage. It provides direct antimicrobial activity against common corneal pathogens. And it protects stromal cells from oxidative injury that can lead to scarring.
This multi-target profile is particularly valuable in neurotrophic keratopathy, where the underlying problem is the loss of nerve-derived trophic factors that normally coordinate all of these processes. A damaged corneal nerve cannot release substance P, calcitonin gene-related peptide (CGRP), or nerve growth factor (NGF), each of which contributes to epithelial maintenance and healing. Tb4 does not replace these specific neurotrophic factors, but it activates enough overlapping downstream pathways to partially compensate for their absence.
The clinical failure of SEER-3 despite promising SEER-1 data raises questions about dose optimization, patient selection, and the natural history of neurotrophic keratopathy. Some patients with neurotrophic keratopathy have sufficient residual nerve function to heal with placebo treatment (vehicle eye drops providing moisture and lubrication). Identifying the subpopulation that has genuine healing failure, rather than slow healing, may be critical for demonstrating Tb4's clinical benefit in future trials.
Implications for Peptide Drug Development
The Tb4 corneal program illustrates both the promise and the difficulty of translating peptide biology into approved therapeutics. The preclinical evidence is robust: more than two decades of animal studies, a clearly defined mechanism of action, and consistent promotion of corneal wound healing across multiple injury models. The Phase 2 data showed clinical signal. The small Phase 3 showed dramatic results. The larger Phase 3 did not confirm them.
This trajectory is common in peptide drug development. Peptides often produce clear effects in controlled preclinical settings where the injury model, dosing schedule, and endpoints are tightly defined. Human disease introduces variability in injury severity, healing capacity, compliance, and placebo response that dilutes the signal. The question is rarely whether Tb4 promotes corneal healing (the biology is clear) but whether the magnitude of benefit is sufficient and consistent enough to meet regulatory endpoints in a heterogeneous patient population.
The development of next-generation Tb4 formulations, including engineered tandem peptides with enhanced stability and delivery optimization, represents an effort to increase the signal by delivering more active peptide to the wound site for longer periods. Whether these improvements will prove sufficient for regulatory approval remains to be determined.
The Bottom Line
Thymosin beta-4 promotes corneal wound healing through actin-mediated cell migration, anti-inflammatory signaling, and antimicrobial effects. The SEER-1 trial showed 60% complete healing versus 12.5% placebo in neurotrophic keratopathy, but the larger SEER-3 trial did not confirm these results. Tb4's combination of wound healing, inflammation control, and infection-fighting properties makes it uniquely suited for corneal applications. The topical eye drop formulation avoids systemic delivery challenges that limit most peptide therapeutics. Clinical development continues as engineered Tb4 variants aim to improve stability and efficacy.